QUVIVIQ

Serial Number 79350361
Registration 7341596
700

Registration Progress

Application Filed
Jul 6, 2022
Under Examination
Approved for Publication
Jan 16, 2024
Published for Opposition
Jan 16, 2024
Registered
Apr 2, 2024

Trademark Image

QUVIVIQ

Basic Information

Serial Number
79350361
Registration Number
7341596
Filing Date
July 6, 2022
Registration Date
April 2, 2024
Published for Opposition
January 16, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 2, 2024
Registration
Registered
Classes
005

Rights Holder

Idorsia Pharmaceuticals Ltd

25
Address
Hegenheimermattweg 91
CH-4123 Allschwil
CH

Ownership History

Idorsia Pharmaceuticals Ltd

Original Applicant
25
CH

Idorsia Pharmaceuticals Ltd

Owner at Publication
25
CH

Idorsia Pharmaceuticals Ltd

Original Registrant
25
CH

Legal Representation

Attorney
Mary Margaret L. O'Donnell

USPTO Deadlines

Next Deadline
1568 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20240402)
Due Date
April 02, 2030
Grace Period Ends
October 02, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

33 events
Date Code Type Description Documents
Nov 2, 2024 FINV P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Oct 17, 2024 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Oct 17, 2024 FIMP P FINAL DISPOSITION PROCESSED Loading...
Jul 3, 2024 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Apr 2, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Apr 2, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jan 16, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 16, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 13, 2024 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Dec 27, 2023 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Dec 27, 2023 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Dec 27, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 11, 2023 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 8, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 7, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 7, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 7, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Dec 7, 2023 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Loading...
Dec 7, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Dec 7, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Dec 7, 2023 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Dec 7, 2023 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jul 4, 2023 RFNT P REFUSAL PROCESSED BY IB Loading...
Jun 10, 2023 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Jun 10, 2023 RFRR P REFUSAL PROCESSED BY MPU Loading...
Apr 27, 2023 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Apr 26, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 20, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 2, 2023 CORR I CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED Loading...
Feb 13, 2023 CRCV M CORRECTION TRANSACTION RECEIVED FROM IB Loading...
Sep 27, 2022 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Sep 23, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 22, 2022 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations intended for the prevention or treatment of cardiovascular diseases, hypertension, cerebral haemorrhages and sequela thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergy diseases, autoimmune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, central nervous system diseases and disorders, dementia, insomnia, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage diseases, Fabry disease and Fabry disease symptoms and sequela, infectious diseases and cancer

Additional Information

Design Mark
The mark consists of the stylized wording "QUVIVIQ" with five circles formingan arch over the "VIV" letters in the mark.

Classification

International Classes
005